key: cord-0964558-edd2tp38 authors: Pastor-Barriuso, R.; Perez-Gomez, B.; Hernan, M. A.; Perez-Olmeda, M.; Yotti, R.; Oteo, J.; Sanmartin, J. L.; Leon-Gomez, I.; Fernandez-Garcia, A.; Fernandez-Navarro, P.; Cruz, I.; Martin, M.; Delgado-Sanz, C.; Fernandez de Larrea, N.; Paniagua, J. L.; Munoz-Montalvo, J. F.; Blanco, F.; Larrauri, A.; Pollan, M. title: SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study date: 2020-08-07 journal: nan DOI: 10.1101/2020.08.06.20169722 sha: fdddb2d560eacdb2d62f4c18ea97ff46e82c108f doc_id: 964558 cord_uid: edd2tp38 The magnitude of the infection fatality risk (IFR) of SARS-CoV-2 remains under debate. Because the IFR is the number of deaths divided by the number of infected, serological studies are needed to identify asymptomatic and mild cases. Also, because ascertainment of deaths attributable to COVID-19 is often incomplete, the calculation of the IFR needs to be complemented with data on excess mortality. We used data from a nation-wide seroepidemiological study and two sources of mortality information -deaths among laboratory-confirmed COVID-19 cases and excess deaths- to estimate the range of IFR, both overall and by age and sex, in Spain. The overall IFR ranged between 1.1% and 1.4% in men and 0.58% to 0.77% in women. The IFR increased sharply after age 50, ranging between 11.6% and 16.4% in men [≥]80 years and between 4.6% and 6.5% in women [≥]80 years. Our IFR estimates for SARS-CoV-2 are substantially greater than IFR estimators for seasonal influenza, justifying the implementation of special public health measures. ≥ 80 years. Our IFR estimates for SARS-CoV-2 are substantially greater than IFR estimators for seasonal influenza, justifying the implementation of special public health measures. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2020. . https://doi.org/10.1101/2020.08.06.20169722 doi: medRxiv preprint a key indicator to design public health policies to control infectious diseases. Because the magnitude of the infection fatality risk (IFR) of SARS-CoV-2 remains under debate, 1,2 lockdowns and other extreme forms of social distancing have been questioned as appropriate responses to the COVID-19 pandemic. An accurate estimation of the IFR of SARS-CoV-2 is difficult. Even if all symptomatic infections were diagnosed, something that so far has not occurred in most countries, asymptomatic infections cannot be clinically identified. Therefore, estimating the IFR needs to rely on well-designed serosurveys that provide an approximation to the proportion of individuals that has been infected, regardless of symptoms. 3 A recent unpublished review of 24 serological reports 4 , several of them also unpublished, estimated an overall IFR of 0.68% (95% CI 0.53-0.83). However, the methodological quality of many of these studies was questionable, IFR estimates were based only on surveillance-registered deaths, and there was a very high between-study heterogeneity, with estimates ranging from 0.16% to 1.60%. Also, because the IFR for SARS-CoV-2 is expected to increase with age, overall IFR estimates cannot be directly compared between populations (e.g., China and Western Europe) with different age structure. Accurate and reliable age-specific estimates of IFR are urgently needed. Here, we report overall and age-and sex-specific IFR estimates for SARS-CoV-2 from ENE-COVID, a large nationally representative serosurvey in Spain. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 7, 2020. . https://doi.org/10.1101/2020.08.06.20169722 doi: medRxiv preprint Overall, the IFR estimate (95% CI) was 0.83% (0.78, 0.89) for confirmed COVID-19 deaths and 1.07% (1.00, 1.15) for excess deaths. The corresponding estimates were 1.11% and 1.40% for men, and 0.58% and 0.77% for women (Table 1) . That is, depending on the source of death data, men were between 81% and 93% more likely to die than women. The IFR estimate varied greatly with age. It was under 1 per 1000 through age 49, with much lower values in younger age groups, and increased sharply in older age groups ( Figure 1 ). Among men aged 80 years or older, the IFR estimate (95% CI) was 11.6% (8.1, 16.5) for confirmed COVID-19 deaths and 16.4% (11.4, 23. 2) for excess deaths. Among women aged 80 years or older, the corresponding estimates were 4.6% (3.4, 6.3) and 6.5% (4.7, 8.8). We estimated an IFR for SARS-CoV-2 between 0.83% and 1.07% in Spain through July 15, 2020. The IFR was greater in men than in women and increased with age: 11.6% to 16.4% in men aged ≥ 80 years and 4.6% to 6.5% in women aged ≥ 80 years. Because incomplete ascertainment of deaths is unavoidable during a large-scale epidemic, we obtained separate IFR estimates based on confirmed COVID-19 deaths and excess all-cause deaths. The latter include mortality directly due to SARS-CoV-2 infection and net mortality due to the societal impact of the epidemic and its control measures, such as delayed care for emergencies and pre-existing chronic conditions, psychological distress, reductions in traffic injuries and other accidents, 5 etc. Our findings suggest that some of the heterogeneity in published IFR estimates is driven by the different age structure of the population. Our IFR estimates, like others from Italy, 6, 7 are larger than those from countries 4 with a smaller proportion of population in the older age groups. Variations in IFR values may also be explained by the local dynamics of the epidemic (e.g., surge in number of new cases, diffusion of the virus among vulnerable collectives) and the health system capacity to treat severe cases. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 7, 2020. . https://doi.org/10.1101/2020.08.06.20169722 doi: medRxiv preprint The greater mortality in the elderly may result from a greater prevalence of comorbidities (cardiovascular disease, type 2 diabetes, lung and chronic kidney diseases) that are associated with greater COVID-19 mortality, 8 and immunological changes (including a decrease of CD8 T cells 9 ) that affect the severity of SARS-CoV-2 infections. 10, 11 Sex differences in cellular immunity may explain the higher mortality among men, who present a poorer T-cell activation and an increase in proinflammatory cytokines. 12 A negative correlation of T cell response with patients' age was found in males but not in female patients. 12 Because the ENE-COVID serosurvey was conducted among the non-institutionalized Spanish population, we excluded deaths in long-term care facilities from the IFR estimates. However, with an estimated 333,920 people living in nursing homes (76% of them aged 80 or older 13 ) and more than 19 ,000 deaths, the epidemic was particularly serious in these institutions. 14 Further research is needed to characterize the mortality in long-term care facilities with vulnerable populations in which the virus spreads very rapidly. This research, which requires a specific approach, 15, 16 would be helped by the inclusion of specific indicators to monitor these groups in regional and national surveillance systems. The ENE-COVID serosurvey was timed to provide an IFR estimate for first wave of SARS-CoV-2 infection in Spain. 17 The first round of the study started one month after the peak, which took place around March 20, and the last round ended on June 22. Thus, most participants would have been infected one month before their first participation. As IgG antibodies are detected 2-3 weeks after symptom onset in more than 90% of COVID-19 cases 18 and decrease 2-3 months after infection, 19 ENE-COVID is expected to cover infections through at least the first week of June. To include potentially delayed COVID-19 deaths, we included all deaths registered through July 15th. The median delay between onset of symptoms and death in our series -75% of deaths occurring before the 20th day-is similar to previously reported seroconversion times (14-21 days). 18 In conclusion, we estimated IFR estimates for SARS-CoV-2 by age and sex in one of the largest serosurveys in the world. Our overall IFR estimates (from 0.83% to 1.07%) are about 10 times larger than those for seasonal influenza, 20 which provides support for strong control measures. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2020. We declare no competing interests. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2020. Sanitaria. The Spanish Institute of Statistics provided the random selection of households and the information required for participants' contact. We would like to thank all the nurses, general practitioners, administrative personell and other health-care workers who collaborated in this study and all participants. This study is the result of the efforts of many professionals and the trust and generosity of more than 60,000 participants who have understood the interest of providing time, information and samples to learn about the situation of the COVID19 epidemic in our country. The IFR was defined as the number of deaths due to COVID-19 divided by the number of individuals with SARS-CoV-2 infection in the non-institutionalized Spanish population. We calculated the prevalence of IgG antibodies against SARS-CoV-2 in the non-institutionalized Spanish population using data from ENE-COVID, a nationwide population-based serosurvey whose design has been described elsewhere. 21 Briefly, 1,500 census tracts, and 24 households within each tract, were randomly selected using a stratified two-stage sampling. All residents of the 35,883 households were invited to participate in the study, carried out between April 27 and June 22, 2020 in three two-week rounds, with a one-week break between rounds. Epidemiologic questionnaires and serology tests were administered to 68,292 individuals who participated in at least one round. 22 The study used two immunoassays to detect IgG antibodies: a point-of-care test (Orient Gene Biotech COVID-19 IgG/IgM Rapid test Cassette), and a chemiluminiscent microparticle immunoassay (CMI) that required venipuncture (SARS-CoV-2 IgG for use with ARCHITECT; Abbott Laboratories, Abbott Park, IL, USA; reference 06R8620), with better performance characteristics. 21 We calculated the seroprevalence, overall and in strata defined by age and sex, as the proportion of participants who had detectable IgG antibodies against SARS-CoV-2 in any round in the CMI test (61,092 participants had a valid CMI result). To account for the different sampling selection . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2020. . https://doi.org/10.1101/2020.08.06.20169722 doi: medRxiv preprint probabilities by province and to adjust for non-response to the CMI test based on sex, age, and census tract average income, we assigned sampling weights to each study participant. 21 We then calculated the number of seropositive persons in Spain by multiplying the age-and sexspecific prevalences of IgG antibodies times the size of the corresponding non-institutionalized Spanish population groups as of July 15, 2020, provided by the National Institute of Statistics. 23 Given the practical difficulties in reporting and adjudicating deaths from COVID-19 during the epidemic, we estimated the IFR separately using confirmed COVID-19 deaths and excess all-cause deaths. 7 The two sources of information were the Spanish National Epidemiological Surveillance Network (RENAVE) and the Monitoring Mortality System (MoMo). Table 1 ). We subtracted these deaths from those identified by RENAVE and MoMo, respectively, in the population aged 60 years and older (see Supplementary Methods for details). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2020. . https://doi.org/10.1101/2020.08.06.20169722 doi: medRxiv preprint We obtained separate estimates of the overall IFR using the COVID-19 deaths from RENAVE (lower bound of deaths, due to limited ascertainment in surveillance) and the excess all-cause deaths from MoMo (a possible upper bound because of the inclusion of deaths that may not result from direct or indirect effects of the epidemic). We then repeated the above analyses in each stratum defined by sex and 10-year age group. We calculated 95% confidence intervals based on delta methods that accounted for both the binomial variance in the number of deaths and the estimated design-based variance in the number of infections. Analyses were performed using survey commands in Stata, version 16 and survey package in R, version 3. The manuscript includes all figures needed to replicate the IFR estimations and indicate the sources The code for IFR calculation can be requested to rpastor@isciii.es and will be available at https://portalcne.isciii.es/enecovid19/ . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2020. . https://doi.org/10.1101/2020.08.06.20169722 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2020. . https://doi.org/10.1101/2020.08.06.20169722 doi: medRxiv preprint 1 3 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2020. Assessment of Deaths From COVID-19 and From Seasonal Influenza The infection fatality rate of COVID-19 inferred from seroprevalence data Use of serological surveys to generate key insights into the changing global landscape of infectious disease A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates Defunciones según la Causa de Muerte COVID-19: Recovering estimates of the infected fatality rate during an ongoing pandemic through partial data How deadly is COVID-19? A rigorous analysis of excess mortality and age-dependent fatality rates in Italy The natural history of symptomatic COVID-19 in Catalonia, Spain: a multi-state model including 109,367 outpatient diagnoses, 18,019 hospitalisations, and 5,585 COVID-19 deaths among 5,627,520 people The twilight of immunity: emerging concepts in aging of the immune system The trinity of COVID-19: immunity, inflammation and intervention Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes Una estimación de la población que vive en residencias de mayores -EnR? Radiografía del coronavirus en residencias de ancianos: más de 19.600 muertos con COVID-19 o síntomas compatibles Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington High impact of COVID-19 in long-term care facilities, suggestion for monitoring in the EU/EEA Instituto de Salud Carlos III. COVID-19 in Spain Evidence summary of the immune response following infection with SARS-CoV-2 or other human coronaviruses Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Disease Burden of Influenza Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. The Lancet Población en viviendas familiares